| | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine (Vero Cell), Inactivated (CoronaVac®) in . . . |
Terminated |
21 Mar 2023 |
| | A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Inducible Urticaria (CINDU) in adolescents . . . |
Pending |
30 Nov -0001 |
| | A Multi-national, Multi-center, Randomized, Double-Blind, Active-Controlled, Phase III Study to Investigate the Efficacy and Safety of 'GC3107 (BCG Vaccine)' after Intradermal Administration in Health . . . |
Ongoing |
24 Jun 2021 |
| | A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenance of response in participants with non-radiographic axial sp . . . |
Ongoing |
28 Apr 2023 |
| | A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696 . . . |
Completed |
25 Jan 2022 |
| | A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab to demonstrate long-term efficacy, safety and tolerability in subjects with moderate to severe hidradenit . . . |
Ongoing |
21 May 2021 |
| | A Multicenter, Open-label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab T . . . |
Ongoing |
04 Apr 2023 |
| | A multicenter, openlabel, follow-up study to assess the longterm use of Lacosamide (flexible dose from 200 to 600 mg/day) used as monotherapy in subjects who completed SP0994 and received Lacosamide m . . . |
Completed |
23 Sep 2020 |
| | A multicenter, randomized, 52-week, double-blind, parallel group, active controlled study to compare the efficacy and safety of QVM149 with QMF149 in patients with asthma . . . |
Completed |
23 Apr 2020 |
| | A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 in Adult Participants with Active Systemic Lupus Erythematosus . . . |
Ongoing |
30 Mar 2023 |
| | A multicenter, randomized, double-blind, active-controlled, 2 week treatment, parallel-group study to assess the efficacy and safety of indacaterol acetate delivered via the Concept1 inhalation device . . . |
Completed |
30 Mar 2021 |
| | A multicenter, randomized, double-blind, active-controlled, parallel-group phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk pat . . . |
Completed |
26 Jan 2022 |
| | A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patien . . . |
Completed |
19 Feb 2020 |
| | A multicenter, randomized, double-blind, placebo controlled phase III study to evaluate the efficacy, safety and tolerability of serelaxin when added to standard therapy in acute heart failure patient . . . |
Terminated |
25 Jan 2022 |
| | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of MW33 Injection to Evaluate the Efficacy and Safety in Patients with Mild or Moderate COVID-19 . . . |
Ongoing |
29 Jul 2021 |
| | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Backg . . . |
Pending |
16 Mar 2022 |
| | A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety, of SA237 as monotherapy in patients with Neuromyelitis Optica (NMO) and Neuromyelitis Op . . . |
Completed |
29 Jul 2021 |
| | A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52-Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With . . . |
Ongoing |
11 Aug 2021 |
| | A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants with Active Systemic Lupus Erythematosus (AZALEA) . . . |
Ongoing |
08 Jun 2022 |
| | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK119 in Healthy Sub . . . |
Terminated |
16 Sep 2021 |
| | A Phase 1/2 Double-Blind, Randomized, Placebo-Controlled Study of TL-895 with Standard Available Treatment versus Standard Available Treatment for the Treatment of Patients Hospitalized for COVID-19 . . . |
Terminated |
04 Jan 2021 |
| | A Phase 1b Randomized, Double-blind, Placebo-controlled, Multiple Ascending-dose Study of EQ001 in Subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis . . . |
Terminated |
28 Nov 2022 |
| | A Phase 2 Randomized, Double-blind, Placebo-controlled Safety and Efficacy Trial of Deupirfenidone (LYT-100) in Post-acute COVID-19 Respiratory Disease . . . |
Ongoing |
20 Jan 2021 |
| | A Phase 2 Study of Cemdisiran in Adult Patients with IgA Nephropathy |
Ongoing |
07 Oct 2019 |
| | A Phase 2 study to assess the safety and immunogenicity of a new typhoid vaccine compared to current typhoid vaccine in healthy Filipino Infants and Toddlers . . . |
Completed |
25 Jan 2021 |